The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (£272m) over five years over Washington's insistence on sensitive biological samples.
The decision became public following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesman later explained that the United States was seeking health data for research and profit while refused to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further dialogue to secure a deal acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Context
This development follows a similar case in Kenya, where a high court halted a related deal with the US after concerns were filed about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
According to reports, Sixteen nations in Africa have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, with no corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our country would supply the basic resources for medical research with no assurance that the final treatments would be available to our population should a new pandemic arise."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its push of one-on-one health agreements were disrupting systems previously set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This system is designed to ensure that when a nation provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how future collaboration might be structured in a way that respects the independence and interests of each country."
Medical Community Reaction
Medical experts said it recognised the official position, but suggested that negotiations need to persist considering a large portion of the nation's HIV programmes relied on international support.
"In cases where specific concerns exist, such as those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it added.
The situation emphasises the ongoing challenges between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.